EGFR and non-small cell lung carcinoma: Recent tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, afatinib, and osimertinib, have been shown to improve outcomes in cases of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer brain metastasis (NSCLC-BM) [1,2,3]; however, an inability to penetrate the central nervous system is a limiting factor.